SMARCE1 and meningioma: We next used targeted next-generation sequencing to gain insight into the mutational landscape of the meningiomas in this cluster and identified mutations in SMARCE1 in 33 of the 34 cases (97%) with sufficient material available (Fig. 2 and Suppl.